NBIX · Neurocrine Biosciences Inc
$180.79
-2.04 (-1.12%)
At close · Jul 29
Earnings today
Market Cap
$18.18B
Shares
100.55M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$500,000,000
as of 2025-02-28
Remaining Authorization
$276,300,000
as of 2026-03-31
Program Utilization
44.7%
$223,700,000 used of $500,000,000
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-03-31 YTD | $54,000,000 | 10-Q, filed 2026-05-05 | ||
| 2025-12-31 | $167,700,000 | 10-K, filed 2026-02-11 | ||
| 2024-12-31 | $300,000,000 | 10-K, filed 2026-02-11 | ||
Key facts
CIK
914475
CUSIP
64125C109
13F (30d)
233 filings
206 filers
Visit website
Investor relations